NCT01593072撤回1 期
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- The outcome measures are Serial PK Day 1 over 24 hrs(pre-dose,10 min post,30 min post, 1hr 1.5,2,4,6, 8, 12,16,24,28,32,36, and 48 hrs post-dose), daily through level and on Day 14 (last day of dosing) serial PK until 48 hrs post last dose.
研究概览
简要总结
The purpose of this study is to evaluate the safety and tolerability of healthy male and female subjects with intravenous (IV) infusions of AVI 7537 compared to matched placebo in and to evaluate the pharmacokinetics (PK).
详细描述
The purpose of this study is to evaluate the safety and tolerability of 14 once daily intravenous (IV) infusions of ascending doses of AVI 7537 compared to matched placebo in healthy male and female subjects.
To evaluate the pharmacokinetics (PK) of 14 once daily doses of AVI-7537 in healthy male and female subjects
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •A subject must meet all of the following criteria to be eligible for this study.
- •Man or woman 18 to 50 years of age, inclusive, at the time of screening.
- •Body mass index 18 kg/m2 to 35 kg/m2, inclusive, at the time of screening and Check-in (Day -1).
- •Good general health (no chronic health conditions) as determined by the Investigator.
- •Female subjects must be of non-childbearing potential (e.g., be confirmed post-menopausal or have undergone surgical sterilization) or must, in conjunction with their sexual partner(s), use 2 forms of medically acceptable contraception (e.g., oral contraception in conjunction with a male condom) during the screening period and for the entire duration of the study including the 28-day post last dose follow-up.
- •Male subjects must either be sterile or agree to use, for the entire duration of the study including the 28 day post last dose follow-up, a male condom and the female sexual partner must also use a medically acceptable form of birth control (e.g. oral contraceptives).
- •Male subjects must agree to not donate sperm for at least 30 days after the last infusion of study medication.
- •Able to understand the requirements of the study, to provide written informed consent (as evidenced by signature on an informed consent document that is approved by an Institutional Review Board [IRB]), and agreeable to abiding by the study restrictions.
排除标准
- •A subject who meets any of the following criteria will be excluded from this study.
- •Pregnancy or breastfeeding.
- •A positive urine or blood screen for drugs of abuse, including alcohol.
- •Use of any tobacco- or nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months prior to Check-in (Day -1).
- •A positive cotinine test indicating recent nicotine use.
- •Donated blood within 90 days or plasma within 30 days of first dose on Day
- •Active substance abuse or any medical or psychiatric condition that could jeopardize the subject's safety or the subject's ability to comply with the protocol.
- •Use of any medications apart from vitamins, acetaminophen, or hormonal contraception within 14 days of first dose on Day
- •Subjects with mild seasonal allergies may use antihistamines at the discretion of the Investigator after approval by the Sponsor Medical Monitor.
- •Participation in any interventional clinical trial within 45 days of first dose on Day 1 (i.e., received any other investigational drug).
- •Recipient of an organ transplant (solid or hematopoietic).
- •Prolonged QTcF interval > 440 ms for males or > 460 ms for females using the average of the triplicate electrocardiograms (ECGs) collected during screening, on Day -1, or just prior to dosing on Day
- •Other clinically significant ECG abnormality, as determined by the Investigator.
- •Any clinically significant abnormal hematology, chemistry, coagulation, or urinalysis value, as determined by the Investigator.
- •Glomerular filtration rate (GFR) of < 80 mL/min, based on the Modification of Diet in Renal Disease equation.
- •Urine-albumin-to-creatinine ratio (UACR) > 30 mg/g.
- •Positive test for human immunodeficiency virus (HIV-1 serology) or known HIV infection.
- •Positive result for hepatitis B surface antigen (HBsAg) or for hepatitis C virus (HCV) antibody.
- •Use of alcohol-containing foods or beverages within 72 hours prior to Check-in on Day -
- •Use of caffeine-containing foods or beverages within 24 hours prior to Check-in on Day -
- •Febrile illness or significant infection within 48 hours before administration of the first dose of study drug on Day
- •Note: Inclusion of each subject will be reviewed with a member of AVI BioPharma Clinical Personnel prior to enrollment in the trial. Written approval from a member of AVI BioPharma Clinical Personnel is required prior to randomization.
研究组 & 干预措施
AVI-7537
Active Comparator
AVI-7537
干预措施: AVI-7537 (Drug)
Placebo
Other
Normal Saline Solution (NSS)
干预措施: Normal Saline Solution (NSS) (Other)
结局指标
主要结局
The outcome measures are Serial PK Day 1 over 24 hrs(pre-dose,10 min post,30 min post, 1hr 1.5,2,4,6, 8, 12,16,24,28,32,36, and 48 hrs post-dose), daily through level and on Day 14 (last day of dosing) serial PK until 48 hrs post last dose.
时间窗: 2 weeks
The outcome measures are Serial PK Day 1 over 24 hours (pre-dose, 10 minutes post-dose , 30 minutes, 1 hour, 1.5, 2, 4, 6,. 8, 12,16,24 hours post-dose), daily trough level and on Day 14 (last day of dosing). PK Day 14 over 48 hours (post-dose, 10 minutes, 1.5, 2, 4, 6, 8, 12, 16, 24, 28, 32, 36, and 48 hours post-dose (collection of plasma pre-dose on Day 14 will also serve as the trough sample for that day).
次要结局
- To evaluate the pharmacokinetics (PK) of 14 once daily doses of AVI-7537 in healthy male and female subjects,(2 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult VolunteersMarburg Hemorrhagic FeverNCT01566877Sarepta Therapeutics, Inc.40
已完成
1 期
Safety And Pharmacokinetic Assessment Of Orally Administered Tafamidis In Healthy VolunteersTTR CardiomyopathyNCT01655511Pfizer9
已完成
1 期
Multiple Ascending Dose Study of CTP-692 in Healthy VolunteersHealthyNCT03880253Concert Pharmaceuticals30
已完成
1 期
Multiple Ascending Dose Study in Healthy VolunteersHealthyNCT02404922Concert Pharmaceuticals30
已完成
1 期
Study of Inhaled DMC-IH1 and Intramuscular (EpiPen®) Epinephrine in Healthy Male and Female Participants.Anaphylactic ReactionNCT06013150De Motu Cordis24